Targeting PLD2 in adipocytes augments adaptive thermogenesis by improving mitochondrial quality and quantity in mice.
Hyung Sik KimMin Young ParkNam Joo YunHye Sun GoMi Young KimJe-Kyung SeongMinyoung LeeEun Seok KangJaewang GhimSung Ho RyuBrian A ZabelAra KohYoe-Sik BaePublished in: The Journal of experimental medicine (2021)
Phospholipase D (PLD)2 via its enzymatic activity regulates cell proliferation and migration and thus is implicated in cancer. However, the role of PLD2 in obesity and type 2 diabetes has not previously been investigated. Here, we show that during diet-induced thermogenesis and obesity, levels of PLD2 but not PLD1 in adipose tissue are inversely related with uncoupling protein 1, a key thermogenic protein. We demonstrate that the thermogenic program in adipose tissue is significantly augmented in mice with adipocyte-specific Pld2 deletion or treated with a PLD2-specific inhibitor and that these mice are resistant to high fat diet-induced obesity, glucose intolerance, and insulin resistance. Mechanistically, we show that Pld2 deletion in adipose tissue or PLD2 pharmacoinhibition acts via p62 to improve mitochondrial quality and quantity in adipocytes. Thus, PLD2 inhibition is an attractive therapeutic approach for obesity and type 2 diabetes by resolving defects in diet-induced thermogenesis.
Keyphrases
- insulin resistance
- high fat diet induced
- adipose tissue
- high fat diet
- type diabetes
- polycystic ovary syndrome
- metabolic syndrome
- glycemic control
- skeletal muscle
- cardiovascular disease
- quality improvement
- stem cells
- mass spectrometry
- drug delivery
- single cell
- squamous cell carcinoma
- blood glucose
- papillary thyroid
- newly diagnosed
- squamous cell
- fatty acid